Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with or without radiotherapy in locally advanced head and neck squamous cell carcinoma
NCT07554768Phase 2Not yet recruiting
- Sponsor
- Chen Chunyan
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adebrelimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Chen Chunyan. Primary endpoint: Major Pathological Response Rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07554768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554768.